Traders eyeing biotech swing plays consider ADAP attractive due to recent breakout patterns and improving market breadth indicators. Last week's US$14m market cap gain would probably be appreciated by institutional investors, especially after a year of 68% losses. Our video reports and analysis, with early access to exclusive, subscriber-only videos With ADAP’s Phase II trial announcement approaching, volatility could rise. Market models suggest a scenario where favorable data lifts stock value by 20%. Traders should monitor options activity for clues.